Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older at the time of registration
• People with a general health/activity level rated at 0, 2, or anywhere in between on a standard medical scale (called ECOG), assessed within the 30 days before joining
• People with a suspected stage II to IVB oral cavity cancer (affecting areas such as the tongue, floor of the mouth, cheek lining, gums, a jaw area called the retromolar trigone, lips, or hard palate) where surgery is considered a possible treatment option
• People whose main tumour is at least 2 cm in size and large enough for a small research tissue sample to be taken before the study begins
• People who have not previously received chemotherapy or immunotherapy for their oral cavity cancer; any treatment for a completely separate cancer must have been completed more than 30 days before joining
• People who are able and willing to use contraception during the study treatment and for 100 days afterwards (applies to people who could potentially become pregnant)
• People who could potentially become pregnant must have a negative blood pregnancy test within 7 days before starting treatment
• People whose liver, kidneys, and other organs are functioning at a level the trial site considers adequate

Who may not be able to join:

• People who have been diagnosed with an autoimmune disease — though some conditions may be exceptions, such as well-controlled type 1 diabetes, certain thyroid conditions, rheumatoid arthritis, vitiligo, or alopecia areata that does not require immune-suppressing medication (confirm with trial site)
• People who are currently pregnant or breastfeeding
• People who have another active or progressing cancer currently requiring treatment — exceptions may include certain skin cancers, some early-stage cancers confined to one area, or a cancer from which the person has been free for at least three years (confirm with trial site)
• People who have previously received certain types of immunotherapy drugs that target specific immune checkpoint proteins (known as anti-PD-1, anti-PD-L1, anti-PD-L2, or similar agents)
• People who have previously received radiation therapy or any systemic anti-cancer treatment — including experimental treatments — for the head and neck cancer being studied
• People who have received a live vaccine within 30 days before the first dose of study treatment (examples include vaccines for measles, mumps, rubella, chickenpox, yellow fever, rabies, and some typhoid or influenza nasal spray vaccines)
• People who have a history of lung inflammation (not caused by infection) that required steroid treatment, or who currently have lung inflammation
• People who have previously had an organ or tissue transplant from another person
• People who currently require regular doses of steroid medications (at a level of 10 mg or more of prednisone daily, or an equivalent) or other medications that suppress the immune system
• People who have cancer that has spread to the brain or the lining around the brain, even if it is not causing symptoms or has been treated before
• People who have severe bleeding (grade 3–4) related to their cancer
• People with a known HIV infection, or active or ongoing hepatitis B or hepatitis C infection; certain specific blood markers for hepatitis B also make a person ineligible (confirm with trial site for the detailed hepatitis B exceptions)
• People with known psychiatric conditions or substance use disorders that would make it difficult to participate in the study requirements
• People who are not able to give their own independent legal consent to participate

Important: Always verify eligibility with the trial site directly before applying.